Epiphron Capital

Epiphron Capital is a healthcare-focused private equity firm that invests in early-stage biopharma and biotechnology companies, operating through entities based in Hong Kong, London, and Belgium. The firm manages multiple investment vehicles, including Epiphron Capital Fund I, L.P., which registered with the Cayman Islands Monetary Authority in August 2020, and Epiphron Capital Fund V GP Limited. The organization provides capital and strategic support to life sciences ventures, holding early investments in portfolio companies such as BeyondSpring and its subsidiary Seed Therapeutics. Key figures associated with the firm's international operations and leadership include director Timothy Mark Fletcher Ferdinand, authorized signatory Sherry Xiaoyu Liu, and former partner Edward Dongheng Liu. In September 2022, the firm's Hong Kong entity executed a notable shareholder support agreement, though the organization's exact founding year and original founders are not publicly disclosed.